ADVERTISEMENT
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Globe Newswire
Press release content from Globe Newswire. The AP news staff was not involved in its creation.

BIMI International Medical Inc. Announces Third Quarter 2021 Financial Results

November 15, 2021 GMT

NEW YORK, Nov. 15, 2021 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (NASDAQ: BIMI) (“BIMI” or the “Company”), a leading healthcare products and services provider, today announced its unaudited financial results for the third quarter ended September 30, 2021.

Third Quarter 2021 Highlights:

  • Revenues. Revenues for the three months ended September 30, 2021 increased to $13,777,494 from $3,091,071 in the comparable period in 2020, an increase of $10,686,423, or 345.7%.

  • Gross profit. Gross profit for the three months ended September 30, 2021 increased to $2,029,109 from $257,278 in the comparable period in 2020, an increase of $1,771,831, or 688.7%.

“We are glad to achieve significant revenue growth in the third quarter. The growth was mainly driven by the increase in sales of wholesale pharmaceuticals. Contributing to the increase in revenues for the three months ended September 30, 2021, was the operations of our recently-acquired five hospitals”, said Mr. Tiewei Song, Chief Executive Officer and President of BIMI International Medical Inc. “Looking ahead, we plan to form partnerships with hospitals with regional reputations, with the goal of making quality medical care more accessible to the wider public, especially in less- developed areas, and to provide health management and healthcare services for both urban and rural residents in a more inclusive and coherent manner.”

ADVERTISEMENT

Three and Nine Month Financial Results

ADVERTISEMENT

  • Revenues. Revenues for the three months ended September 30, 2021 and 2020 were $13,777,494 and $3,091,071, respectively. Compared with the three months ended September 30, 2020, revenues increased by $10,686,423 in 2021. Revenues for the nine months ended September 30, 2021 and 2020 were $25,202,485 and $7,317,449, respectively. Compared with the same period in 2020, revenues increased by $17,885,036 in 2021.

    Wholesale pharmaceuticals segment. Revenues from the wholesale pharmaceuticals segment for the three months ended September 30, 2021 and 2020 were $8,483,024 and $2,368,785, respectively. Revenues from the wholesale pharmaceuticals segment for the nine months ended September 30, 2021 and 2020 were $14,978,955 and $4,698,985, respectively.

    Wholesale medical devices segment. Revenues from the wholesale medical devices segment for the three months ended September 30, 2021 and 2020 were $1,608,584 and $669,276, respectively. Revenues from the wholesale medical devices segment for the nine months ended September 30, 2021 and 2020 was $2,524,777 and 2,567,029, respectively.

    Medical services segment. Revenues from the recently formed medical services segment for the three months ended September 30,2021 were $2,961,536. Revenue from the medical services segment for the nine months ended September 30, 2021 were $6,694,510.

    Retailpharmacysegment. Revenues from the retail pharmacy segment for the three and nine months ended September 30, 2021 were $133,815 and $375,045, respectively, which were generated from 5 retail pharmacy stores in Chongqing. Revenues from the retail pharmacy segment for the three and nine months ended September 30, 2020, which related to stores in Dalian, were negligible.

  • Cost of revenues. Cost of revenues for the three months ended September 30, 2021 and 2020 were $11,748,385 and $2,833,793, respectively. Cost of revenues for the nine months ended September 30, 2021 and 2020 were $20,616,279 and $6,240,962, respectively.

    Wholesalepharmaceuticalssegment. For the three months ended September 30, 2021 and 2020, the cost of revenues of our wholesale pharmaceuticals segment were $8,835,440 and $2,010,319, respectively. For the nine months ended September 30, 2021 and 2020, the cost of revenues of our wholesale pharmaceuticals segment were $14,598,512 and $3,759,707, respectively.

    Wholesalemedicaldevicessegment. For the three months ended September 30, 2021 and 2020, the cost of revenues of our wholesale medical devices segment were $1,133,768 and $572,886, respectively. For the nine months ended September 30, 2021 and 2020, the cost of revenues of the wholesale medical devices segment were $1,831,089 and $2,051,563, respectively.

    Medical services segment. For the three and nine months ended September 30, 2021, the cost of revenues of the recently acquired medical services segment were $1,240,773 and $3,334,306, respectively.

    Retailpharmacysegment. For the three and nine months ended September 30, 2021, the cost of revenues of our retail pharmacy segment were $99,477 and $295,059, respectively. For the three and nine months ended September 30, 2020, the cost of revenues of our retail pharmacy operations in Dalian were $227,883 and $426,293, respectively, including an inventory impairment charge of $68,600 that resulted from the expiration of a large portion of our products because of the local lockdown.

  • Gross margin. For the three months ended September 30, 2021 and 2020, BIMI had gross margins of 14.7% and 8.3%, respectively. For the three months ended September 30, 2021 and 2020, the gross profit margin of our: (i) wholesale pharmaceuticals segment were (4.2%) and 15.1%, respectively; (ii) wholesale medical devices segment were 29.5% and 14.4%, respectively; (iii) medical services segment was 58.1% in 2021; and (iv) retail pharmacy segment was 25.7% in 2021.

    For the nine months ended September 30, 2021 and 2020, BIMI had gross margins of 18.0% and 14.7%, respectively. For the nine months ended September 30, 2021 and 2020, the gross profit margin of our: (i) wholesale pharmaceuticals segments were 2.5% and 20.0%, respectively; (ii) wholesale medical devices segment were 27.5% and 20.1%, respectively; (iii) medical services segment was 50.2% in 2021; and (iv) retail pharmacy segment was 21.3% in 2021.

  • Operating expenses. Operating expenses were $3,574,443 for the three months ended September 30, 2021 as compared to $1,689,962 for the same period in 2020, an increase of $1,884,481, or 111.5%. Operating expenses were $ 9,522,372 for the nine months ended September 30, 2021 as compared to $6,583,685 for the same period in 2020, an increase of $2,938,687, or 44.6%.

    Wholesalepharmaceuticalssegment. Operating expenses of the wholesale pharmaceuticals segment for the three months ended September 30, 2021 and 2020 were $269,425 and $33,419, respectively. Operating expenses of the wholesale pharmaceuticals segment for the nine months ended September 30, 2021 and 2020 were $750,023 and $497,103, respectively.

    Wholesale medical devices segment. Operating expenses of the wholesale medical devices segment for the three and nine months ended September 30, 2021 were $243,117 and $469,644, respectively. Operating expenses of the wholesale medical devices segment for the three months and nine months ended September 30, 2020 were $435 and $15,293, respectively.

    Medical services segment. Operating expenses of medical services segment for the three and nine months ended September 30, 2021 were $1,136,316 and $2,377,996, respectively.

    Retailpharmacysegment. Operating expenses of the retail pharmacy segment for the three and nine months ended September 30, 2021 were $159,988 and $547,159, respectively. Operating expenses of the retail pharmacy segment for the three and nine months ended September 30, 2020 were $1,391,910 and $2,043,438, respectively.

  • Other income (expenses). For three months ended September 30, 2021, BIMI had $158,612 of other expenses, net that included $74,302 of other expenses and $84,310 of interest expenses. For the nine months ended September 30, 2021, BIMI had $302,142 of other expenses, net that included $79,595 of other expenses and $222,547 of interest expenses.

    For the three months ended September 30, 2020, BIMI reported other income of $5,247 and other interest expense of $339,780. For the nine months ended September 30, 2020, BIMI reported other income of $6,973,409 and other interest expense of $717,226. Other income in both periods includes the gain generated from the disposal of the NF Group.

  • Net income (loss). As a result of the foregoing, our net loss was $1,709,876 and $5,276,241 for the three and nine months ended September 30, 2021. For the three and nine months ended September 30, 2020, BIMI had a net loss of $1,860,573 and net income of $ 611,090, respectively.

  • Cash and working capital. At September 30, 2021, BIMI had cash of $209,803 and working capital of $2.12 million as compared to cash of $135,309 and working capital of $9,619,274 at December 31, 2020.

The unaudited condensed consolidated financial statements included in the quarterly report on Form 10-Q of the Company that was filed on November 15, 2021 have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the discharge of liabilities in the normal course of business for the foreseeable future. The continuation of the Company as a going concern through the next twelve months is dependent upon (1) the continued financial support from its stockholders or external financing, and (2) further implementation of management’s business plan to extend its operations and generate sufficient revenues and cash flow to meet its obligations. Management believes that the actions presently being taken to obtain additional funding and implement its strategic plan provide the opportunity for the Company to continue as a going concern.

About BIMI International Medical Inc.

The Company is now exclusively a healthcare products and services provider, offering a broad range of healthcare products and related services and operates five private hospitals in China. For more information, please visit www.usbimi.com.

Safe Harbor Statement
Certain matters discussed in this news release are forward-looking statements that involve a number of risks and uncertainties including, but not limited to, the Company’s ability to achieve profitable operations, its ability to continue to operate as a going concern, its ability to continue to meet NASDAQ continued listing requirements, the effects of the spread of COVID-19, the demand for the Company’s products and services in the People’s Republic of China, general economic conditions and other risk factors detailed in the Company’s annual report and other filings with the United States Securities and Exchange Commission.

IR Contact:
Dragon Gate Investment Partners LLC Tel: +1(646)-801-2803
Email: BIMI@dgipl.com

BIMI INTERNATIONAL MEDICAL, INC. AND ITS SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS

   September 30,
2021
   December 31,
2020
 
ASSETS Unaudited    
CURRENT ASSETS      
Cash $209,803  $135,309 
Restricted Cash  4,641   - 
Accounts receivable, net  11,621,052   6,686,552 
Advances to suppliers  4,387,191   2,693,325 
Amount due from related parties  441,301   - 
Inventories  2,117,486   735,351 
Prepayments and other receivables  7,521,587   14,880,526 
Operating lease-right of use assets-current  -   53,425 
Total current assets  26,303,061   25,184,488 
NON-CURRENT ASSETS        
Deferred tax assets  204,181   193,211 
Property, plant and equipment, net  2,517,863   910,208 
Intangible assets, net  17,734   - 
Operating lease-right of use assets  3,593,297   - 
Goodwill  30,442,738   6,914,232 
         
Total non-current assets  36,775,813   8,017,651 
         
TOTAL ASSETS $63,078,874  $33,202,139 
         
LIABILITIES AND EQUITY        
CURRENT LIABILITIES        
Short-term loans $1,143,183  $904,228 
Long-term loans due within one year  -   34,201 
Convertible promissory notes, net  4,831,736   3,328,447 
Accounts payable, trade  13,469,931   5,852,050 
Advances from customers  392,485   194,086 
Amount due to related parties  839,473   226,514 
Taxes payable  665,405   773,649 
Other payables and accrued liabilities  2,142,202   4,228,976 
Lease liabilities-current  702,789   23,063 
         
Total current liabilities  24,187,204   15,565,214 
         
Long-term loans – non-current portion  794,538   720,997 
Lease liabilities -non-current  3,308,881   22,457 
TOTAL LIABILITIES $28,290,623   16,308,668 
         
COMMITMENTS AND CONTINGENCIES        
         
EQUITY        
Common stock, $0.001 par value; 50,000,000 shares authorized; 32,423,350 and 13,254,587 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively  32,423   13,254 
Additional paid-in capital  49,580,126   26,344,920 
Statutory reserves  2,263,857   2,263,857 
Accumulated deficits  (18,227,631)  (12,914,973)
Accumulated other comprehensive income  880,807   1,003,392 
         
Total BIMI International Medical Inc.’s equity  34,529,582   16,710,450 
         
NONCONTROLLING INTERESTS  258,669   183,021 
         
Total equity  34,788,251   16,893,471 
         
Total liabilities and equity $63,078,874   33,202,139 

The accompanying notes are an integral part of the condensed consolidated financial statements

BIMI INTERNATIONAL MEDICAL, INC. AND ITS SUBSIDIARIES 
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME
(UNAUDITED)

   For the three months ended
September 30
   For the nine months ended
September 30
 
  2021  2020  2021  2020 
             
REVENUES $13,777,494  $3,091,071   25,202,485  $7,317,449 
                 
COST OF REVENUES  11,748,385   2,833,793   20,616,279   6,240,962 
                 
GROSS PROFIT  2,029,109   257,278   4,586,206   1,076,487 
                 
OPERATING EXPENSES:                
Sales and marketing  1,202,387   377,977   2,429,401   1,028,746 
General and administrative  2,372,056   1,311,985   7,092,971   5,554,939 
Total operating expenses  3,574,443   1,689,962   9,522,372   6,583,685 
                 
LOSS FROM OPERATIONS  (1,545,334)  (1,432,684)  (4,936,166)  (5,507,198)
                 
OTHER INCOME (EXPENSE)                
Interest expense  (84,310)  (339,780)  (222,547)  (717,226)
Other income (expense)  (74,302)  5,247   (79,595)  6,973,409 
Total other income (expense), net  (158,612)  (334,533)  (302,142)  6,256,183 
                 
INCOME (LOSS) BEFORE INCOME TAXES  (1,703,946)  (1,767,217)  (5,238,308)  748,985 
                 
PROVISION FOR INCOME TAXES  5,930   93,356   37,933   137,895 
                 
NET INCOME (LOSS)  (1,709,876)  (1,860,573)  (5,276,241)  611,090 
Less: net income (loss) attributable to non-controlling interest  (6,444)  49,374   36,417   75,648 
NET INCOME (LOSS) ATTRIBUTABLE TO BIMI INTERNATIONAL MEDICAL INC. $(1,703,432) $(1,909,947) $(5,312,658) $535,442 
                 
OTHER COMPREHENSIVE INCOME (LOSS)                
Foreign currency translation adjustment  (128,005)  (108,236)  (126,893)  34,802 
TOTAL COMPREHENSIVE INCOME (LOSS)  (1,837,881)  (1,968,809)  (5,403,134)  645,892 
Less: comprehensive income (loss) attributable to noncontrolling interest  (6,400)  1,193   (6,345)  (1,408)
COMPREHENSIVE INCOME (LOSS) ATTRIBUTABLE TO BIMI INTERNATIONAL MEDICAL INC.  (1,831,481)  (1,970,002)  (5,396,789) $647,300 
                 
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING                
Basic and diluted  27,084,325   10,505,821   22,864,269   9,987,848 
                 
EARNINGS (LOSS) PER SHARE                
Net income (loss) - basic and diluted $(0.06) $(0.19) $(0.23) $0.05 

The accompanying notes are an integral part of the consolidated financial statements

BIMI INTERNATIONAL MEDICAL, INC. AND ITS SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)

   For the nine months ended
September 30
 
  2021  2020 
CASH FLOWS FROM OPERATING ACTIVITIES:      
Net income (loss) $(5,276,241) $611,090 
Adjustments to reconcile net income (loss) to cash provided by (used in) operating activities:        
Depreciation and amortization  179,147   810,264 
Profit on disposal of NF Group  -   (6,944,469)
Stock compensation  585,000   - 
Allowance for doubtful accounts  94,037   (263,260)
Amortization of discount of convertible promissory notes  1,473,306   1,950,901 
Change in derivative liabilities  -   43,224 
Allowance for inventory provision  35,013   390,923 
Impairment loss of intangible assets  -   903,573 
Change in operating assets and liabilities        
Accounts receivable  (5,028,537)  (1,284,400)
Advances to suppliers  (1,693,866)  418,847 
Inventories  (1,417,149)  (2,928,419)
Prepayments and other receivables  2,464,793   (1,245,981)
Operating lease-right of use assets  (3,539,872)  - 
Accounts payable, trade  7,617,880   4,844,674 
Advances from customers  198,399   (707,586)
Taxes payable  (119,214)  (9,368)
Operating lease liabilities  3,966,150   - 
Other payables and accrued liabilities  (2,086,772)  594,793 
Net cash used in operating activities  (2,547,926)  (2,815,194)
         
CASH FLOWS FROM INVESTING ACTIVITIES:        
Cash received from acquisition of Guanzan Group  -   95,220 
Cash received from sale of NF Group  -   10,375,444 
Purchase of property, plant and equipment  (1,804,536)  (121,176)
Net cash provided by (used in) investing activities  (1,804,536)  10,349,488 
         
CASH FLOWS FROM FINANCING ACTIVITIES:        
         
Repayment of short-term loans  (34,201)  (65,516)
Repayment of long-term loans  -   (48,164)
Net proceeds from issuance of convertible promissory notes  4,065,000   3,457,325 
Proceeds from long-term loan  73,541   - 
Proceeds from short-term loans  238,955   27,371 
Amount financed from related parties  171,657   173,547 
         
Net cash provided by financing activities  4,514,952   3,544,563 
         
EFFECT OF EXCHANGE RATE ON CASH  (83,355)  471,155 
         
INCREASE IN CASH  79,135   11,550,012 
         
CASH AND CASH EQUIVALENTS, beginning of period  135,309   36,674 
         
CASH AND CASH EQUIVALENTS, end of period  214,444  $11,586,686 
         
SUPPLEMENTAL CASH FLOW INFORMATION:        
Cash paid for income tax $49,037  $42,130 
Cash paid for interest expense, net of capitalized interest $128,973  $62,636 
         
NON-CASH TRANSACTIONS OF INVESTING AND FINANCING ACTIVITIES        
Issuance of shares of common stock for the equity acquisition of Chongqing Guanzan Technology Co., Ltd. $3,818,000  $2,717,000 
Issuance of shares of common stock for equity acquisition of Zhongshan Chaohu Hospital $3,480,000  $- 
Issuance of shares of common stock for equity acquisition of Guoyitang Hospital $3,820,000  $- 
Issuance of shares of common stock for equity acquisition of Minkang, Qiangsheng and Eurasia hospitals $5,930,619  $- 
Issuance of shares of common stock for prepayment of equity acquisition of Zhuoda  1,452,000   - 
Issuance of shares of common stock  for payment of improvements to offices $696,896   - 
Goodwill recognized from equity acquisition of Zhongshan Chaohu Hospital $10,443,494  $- 
Goodwill recognized from equity acquisition of Guoyitang Hospital $7,154,392  $- 
Goodwill recognized from equity acquisition of Minkang, Qiangsheng and Eurasia hospitals $5,930,619  $- 
Intangible assets recognized from equity acquisition of  Boqi Group $-  $6,443,170 
Outstanding payment for the equity acquisition of Chongqing Guanzan Technology Co., Ltd. $-  $4,414,119 
Outstanding payment for equity acquisition of Zhongshan Chaohu Hospital $6,100,723  $- 
Outstanding payment for equity acquisition of Guoyitang Hospital $6,100,723  $- 
Outstanding payment for equity acquisition of Minkang, Qiangsheng and Eurasia hospitals $9,911,416  $- 
Common stock to be issued upon conversion of convertible promissory notes $679  $5,160,473 

The accompanying notes are an integral part of the consolidated financial statements